Kazmierski W M, Ferguson R D, Knapp R J, Lui G K, Yamamura H I, Hruby V J
Department of Chemistry, University of Arizona, Tucson.
Int J Pept Protein Res. 1992 May;39(5):401-14. doi: 10.1111/j.1399-3011.1992.tb01444.x.
The conformational and pharmacological properties that result from peptide bond reduction as well as the use of secondary amino acids in a series of cyclic peptides related to the mu opioid receptor selective antagonist D-Phe1-Cys2-Tyr3-D-Trp4-Orn5-Thr6-Pen7+ ++-Thr8-NH2 (IV), have been investigated. Peptide analogues that contain [CH2NH] and [CH2N] pseudo-peptide bonds (in primary and secondary amino acids, respectively) were synthesized on a solid support. Substitution of Tyr3 in IV by the cyclic, secondary amino acid 1,2,3,4-tetrahydroisoquinoline carboxylate (Tic) and of D-Trp4 with D-1,2,3,4-tetrahydro-beta-carboline(D-Tca4), gave peptides 4 and 1, respectively. Both analogues displayed reduced affinities for mu opioid receptors. Conformational analysis based on extensive NMR investigations demonstrated that the backbone conformations of 1 and 4 are similar to those of the potent and selective analogue D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH2 (I), while the conformational properties of the side chains of Tic3 (4) and D-Tca4 (1) resulted in topographical properties that were not well recognized by the mu opioid receptor. Peptide bond modifications were made including (Tyr3-psi[CH2NH]-D-Trp4), 3; (Tyr3-psi[CH2N]-D-Tca4), 2; and (Cys2-psi[CH2N]-Tic3), 6. These analogues showed decreases in their mu opioid receptor affinities relative to the parent compounds IV, 1, and 4, respectively. 1H NMR based conformational analysis in conjunction with receptor binding data led to the conclusion that the reduced peptide bonds in 2, 3, 5, and 6 do not contribute to the process of discrimination between mu and delta opioid receptors, and in spite of their different dynamic behaviors (relative to 1 and 4), they are still capable of attaining similar receptor bound conformations, possibly due to their increased flexibility.
对与μ阿片受体选择性拮抗剂D-Phe1-Cys2-Tyr3-D-Trp4-Orn5-Thr6-Pen7 +++-Thr8-NH2(IV)相关的一系列环肽中肽键还原以及仲氨基酸的使用所产生的构象和药理学特性进行了研究。在固相载体上合成了分别含有[CH2NH]和[CH2N]假肽键(分别存在于伯氨基酸和仲氨基酸中)的肽类似物。用环状仲氨基酸1,2,3,4-四氢异喹啉羧酸酯(Tic)取代IV中的Tyr3以及用D-1,2,3,4-四氢-β-咔啉(D-Tca4)取代D-Trp4,分别得到肽4和1。两种类似物对μ阿片受体的亲和力均降低。基于广泛NMR研究的构象分析表明,1和4的主链构象与强效选择性类似物D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH2(I)的构象相似,而Tic3(4)和D-Tca4(1)侧链的构象特性导致其拓扑特性未被μ阿片受体很好地识别。进行了肽键修饰,包括(Tyr3-ψ[CH2NH]-D-Trp4),3;(Tyr3-ψ[CH2N]-D-Tca4),2;和(Cys2-ψ[CH2N]-Tic3),6。这些类似物相对于母体化合物IV、1和4,其对μ阿片受体的亲和力分别降低。基于1H NMR的构象分析结合受体结合数据得出结论,2、3、5和6中还原的肽键对μ和δ阿片受体之间的区分过程没有贡献,尽管它们具有不同的动力学行为(相对于1和4),但它们仍能够获得相似的受体结合构象,这可能是由于它们增加的灵活性。